Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Apr 08, 2024 (filed on Apr 10, 2024)Insider Name:Singer William S.Ownership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:800Price:--
-
Apr 08, 2024 (filed on Apr 10, 2024)Insider Name:Silverman JoshuaOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:800Price:--
-
Apr 08, 2024 (filed on Apr 10, 2024)Insider Name:Schechter JonathanOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:800Price:--
-
Apr 08, 2024 (filed on Apr 10, 2024)Insider Name:Bernstein BruceOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:800Price:--
Filings by filing date
-
Apr 08, 2024 (filed on Apr 10, 2024)Insider Name:Singer William S.Ownership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:800Price:--
-
Apr 08, 2024 (filed on Apr 10, 2024)Insider Name:Silverman JoshuaOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:800Price:--
-
Apr 08, 2024 (filed on Apr 10, 2024)Insider Name:Schechter JonathanOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:800Price:--
-
Apr 08, 2024 (filed on Apr 10, 2024)Insider Name:Bernstein BruceOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:800Price:--
News
Biz Brief
Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 1185 AVENUE OF THE AMERICAS, 3RD FLOOR NEW YORK NY 10036 |
Tel: | N/A |
Website: | https://www.synaptogen.com |
IR: | See website |
Key People | ||
Daniel L. Alkon President, Chief Scientific Officer, Director | Alan J. Tuchman Chief Executive Officer, Director | Robert Weinstein Chief Financial Officer, Executive Vice President, Treasurer, Secretary |
Business Overview |
Synaptogenix, Inc. is a clinical-stage biopharmaceutical company developing therapeutics for neurodegenerative disorders. The Company is principally focused on developing a product platform based upon a drug candidate called Bryostatin-1, which is synthesized from a natural product (bryostatin) that is isolated from a marine invertebrate organism, for the treatment of Alzheimer's disease (AD), which is in the clinical testing stage. Preclinical studies have also demonstrated bryostatin's regenerative mechanisms of action for the rare disease Fragile X syndrome, and for other neurodegenerative disorders. It is also evaluating potential therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, Multiple Sclerosis (MS), and Niemann-Pick Type C disease, which have undergone pre-clinical testing. It has conducted clinical and preclinical studies of its lead therapeutic candidate, Bryostatin-1, in AD. |
Financial Overview |
For the fiscal year ended 31 December 2023, Synaptogenix Inc revenues was not reported. Net loss applicable to common stockholders increased from $5.7M to $13.8M. Higher net loss reflects Change in fair value of warrant liabilit decrease of 84% to $1.4M (income), FV Adjustments of Financial Investments decrease from $1.8M (income) to $744K (expense). |
Employees: | 5 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | N/A |
Annual revenue (TTM): | $0.00M as of Dec 31, 2023 |
EBITDA (TTM): | -$8.31M as of Dec 31, 2023 |
Net annual income (TTM): | -$13.78M as of Dec 31, 2023 |
Free cash flow (TTM): | -$5.18M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 1,085,333 as of Apr 5, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |